uploads/2018/02/Chart-006-4-1.jpg

A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17

By

Updated

Neuroscience portfolio

Eli Lilly and Company’s (LLY) human pharmaceutical segment includes neuroscience products Cymbalta, Strattera, Prozac, and Zyprexa. Overall sales for neuroscience products fell in 4Q17 due to lower Strattera, Prozac, and Zyprexa sales, and were partially offset by strong Cymbalta sales.

Article continues below advertisement

Cymbalta

The above chart shows Eli Lilly’s neuroscience revenue since 1Q16. Cymbalta, an antidepressant drug, generated revenue of $192.8 million in 4Q17, marking 6.0% growth from the $181.8 million reported in 4Q16. The growth was driven by ~15% growth in international sales, and partially offset by 2% due to foreign exchange and a ~39.0% decline in US sales to $14.1 million. Other antidepressant drugs include Pfizer’s (PFE) Zoloft, Bristol-Myers Squibb’s (BMY) and Otsuka Pharmaceutical’s Abilify, and Allergan’s (AGN) Fetzima.

Strattera

Strattera, a drug for attention-deficit and hyperactivity disorders, generated revenue of $98.3 million in 4Q17, representing a ~60.0% fall from the $243.2 million seen in 4Q16. The decline was due to lower US sales and partially offset by strong international sales. US sales fell ~95.0% to $8.0 million, while international sales rose ~3.0% to $90.3 million.

Zyprexa

Zyprexa, an antipsychotic drug, generated revenue of $152.2 million in 4Q17, representing a ~1.0% decline from the $153.0 million reported in 4Q16. The decline was due to lower international sales and partially offset by strong US sales. US sales rose ~161.0% to $26.2 million, while international sales fell 12% to $126.0 million.

Advertisement

More From Market Realist